Keith Thomas Flaherty, M.D.
This page shows the publications co-authored by Keith Flaherty and Ryan Sullivan.
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013 Oct 01; 19(19):5283-91.
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013 Apr; 49(6):1297-304.
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer. 2011; 2011:423239.
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 01; 120(11):1695-701.
Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53.
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95.
Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32.
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.